FDA Approves TYMLOS — Radius Health, Inc.

Radius Health Inc.'s TYMLOS (abaloparatide) received FDA approval on April 28, 2017, introducing a new subcutaneous anabolic therapy that directly challenges the market dominance of osteoporosis treatments like Amgen’s Prolia. This regulatory green light positions Radius to leverage its proprietary technology, allowing it to capture significant share in the fast-growing bone-turnover market with a drug designed to improve bone density more rapidly than standard treatments.